AR059956A1 - Derivados de fenetalonamina , procesos de preparacion y composiciones farmaceuticas que los contienen - Google Patents

Derivados de fenetalonamina , procesos de preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
AR059956A1
AR059956A1 ARP070100967A ARP070100967A AR059956A1 AR 059956 A1 AR059956 A1 AR 059956A1 AR P070100967 A ARP070100967 A AR P070100967A AR P070100967 A ARP070100967 A AR P070100967A AR 059956 A1 AR059956 A1 AR 059956A1
Authority
AR
Argentina
Prior art keywords
ring
alkyl
optionally substituted
halogen
phenyl
Prior art date
Application number
ARP070100967A
Other languages
English (en)
Inventor
Michael Stocks
Premji Meghani
Lilian Alcaraz
Andrew Bailey
Garry Pairaudeau
Rhona Cox
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR059956A1 publication Critical patent/AR059956A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)

Abstract

Procesos para su preparacion y composiciones farmacéuticas que los contienen y su uso en terapia. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde Ar es un compuesto seleccionado del grupo de formulas (2); M es C(O), NR6, S o CR7R8; R2, R3, R4 y R5 son, en forma independiente, hidrogeno, halogeno, trifluorometilo, ciano, carboxi, hidroxi, nitro, S(O)2R9, NR10S(O)2R11, C(O)NR12R13, NR14C(O)R15, alquilo C1-6, alcoxi C1-6, C(O)(alquilo C1-6) o C(O)2(alquilo C1-6); R3 también puede ser CH2OH o NHS(O)2NR17R18; X es un enlace, CR27R28 o CR29R30CR31R32; Y es CR33R34CR35R36, CR37R38CR39R40CR41R42 o CR43R44CR45R46CR47R48CR49R50; o Y es CR51R52 con la condicion de que E es C(O)O-; Z es un enlace, CR51R52, CR53R54CR55R56, CR57R58CR59R60CR61R62 o CR63R64CR65R66CR67R68CR69R70; A es un grupo cicloalquilamino seleccionado entre un compuesto del grupo de formulas (3), en donde dicho anillo cicloalquilo no está sustituido o está sustituido con 1 o 2 sustituyentes seleccionados en forma independiente entre halogeno, alquilo C1-4 (opcionalmente sustituido con OR116, NR117R118 o NR119C(O)R120), OR19, NR20R21, C(O)NR22R23, NR24C(O)R25, CN, S(O)2R16, o S(O)2NR114R115; cuando A es un grupo cicloalquilamino A está unido a X a través de un átomo de carbono del anillo y a Y a través de NR26; o cuando A es un grupo cicloalquilamino y X es CR29R30CR31R32 A puede estar unido a X a través de NR26 y a Y a través de un átomo de carbono del anillo; cuando X es un enlace A no está conectado a X a través del átomo de carbono del anillo que lleva a NR26; o A es un anillo heterociclilo seleccionado entre un compuesto del grupo de formulas (4) en donde el anillo heterociclilo no está sustituido o está sustituido con 1 o 2 sustituyentes (por ejemplo un sustituyente está en el mismo átomo de carbono del anillo que el que une A a X o Y) seleccionados en forma independiente entre halogeno, alquilo C1-4 (opcionalmente sustituido con OR121, NR122R123 o NR124C(O)R125), OR19, NR20R21, C(O)NR22R23, NR24C(O)R25, CN, S(O)2R126 o S(O)2NR114R115; cuando A es un anillo heterociclilo A está unido a Y a través de un átomo de nitrogeno del anillo; cuando A es un anillo heterociclilo A puede estar unido a X a través de un átomo de carbono del anillo; o, cuando A es heterociclilo con 2 átomos de nitrogeno del anillo y X es CR29R30CR31R32, A puede estar unido a X a través del segundo átomo de nitrogeno del anillo; E es O, S, S(O)2, NR71, C(O)NR72, NR73C(O), C(O)O, S(O)2NR74 o NR75S(O)2; R1 es arilo, ariloxi, NR76-arilo, S(O)2arilo, heteroarilo o cicloalquilo C3-10 (opcionalmente sustituido con alquilo C1-6, halogeno o fenilo), en donde los anillos arilo y heteroarilo están opcionalmente sustituidos con halogeno, ciano, trifluorometilo, fenilo, OCF3, O(CF2)nO, O(CH2)mO, OR78, SR79, NR80R81, C(O)NR82R83, NR84S(O)2R85, C(O)R86, S(O)2R87, S(O)2NR88R89, NR90C(O)R91, C(O)OR92, alquilo C1-6 (opcionalmente sustituido con fluoro, trifluorometilo, fenilo, heteroarilo, OR93, NR94R95, C(O)NR96R97, NR98S(O)2R99, S(O)2R100 o S(O)2NR101R102) o alcoxi C1-6 (opcionalmente sustituido con fluoro, trifluorometilo, fenilo, heteroarilo, OR103, NR104R105, C(O)NR106R107, NR108S(O)2R109, S(O)2R110 o S(O)2NR111R112); en donde 2 sustituyentes sobre el anillo arilo o heteroarilo que es R1 pueden juntarse para formar un anillo de entre 4 y 8 miembros que es carbocíclico o heterocíclico (por ejemplo que contiene 1, 2, 3 o 4 heteroátomos seleccionados en forma independiente entre O, N y S), dicho anillo de entre 4 y 8 miembros está fusionado y está opcionalmente sustituido con halogeno, alquilo C1-4, CF3 o alcoxi C1-4; cuando Z es un enlace E también puede ser C(O) con la condicion de que R1 sea un grupo seleccionado entre un compuesto del grupo de formulas (5) que está opcionalmente sustituido como para R1; n y m son, en forma independiente, 1 o 2; R6, R7, R8, R10, R12, R13, R14, R15, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R86, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R101, R102, R103, R104, R105, R106, R107, R108, R111, R112, R113, R114, R115, R116, R117, R118, R119, R120, R121, R122, R123, R124 y R125 son, en forma independiente, hidrogeno o alquilo C1-6; R52 también puede ser fenilo; R72 también puede ser fenil(alquilo C1-4) (por ejemplo bencilo); R9, R11, R16, R85, R87, R99, R100, R109, R110 y R126 son, en forma independiente, alquilo C1-6; con la condicion de que cuando R1 es ariloxi, NR76-arilo o S(O)2arilo, y E es O, S, S(O)2, NR71, C(O)NR72, S(O)2NR74 o NR75S(O)2, entonces Z es CR53R54CR55R56, CR57R58CR59R60CR61R62 o CR63R64CR65R66CR67R68CR69R70; o una sal aceptable para uso farmacéutico del mismo.
ARP070100967A 2006-03-08 2007-03-08 Derivados de fenetalonamina , procesos de preparacion y composiciones farmaceuticas que los contienen AR059956A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78025106P 2006-03-08 2006-03-08
US78951606P 2006-04-05 2006-04-05
US83109106P 2006-07-14 2006-07-14

Publications (1)

Publication Number Publication Date
AR059956A1 true AR059956A1 (es) 2008-05-14

Family

ID=38475143

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100967A AR059956A1 (es) 2006-03-08 2007-03-08 Derivados de fenetalonamina , procesos de preparacion y composiciones farmaceuticas que los contienen

Country Status (6)

Country Link
EP (1) EP2013197A1 (es)
JP (1) JP2009529042A (es)
AR (1) AR059956A1 (es)
TW (1) TW200745084A (es)
UY (1) UY30195A1 (es)
WO (1) WO2007102771A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
US8703821B2 (en) 2006-04-18 2014-04-22 Emisphere Technologies Inc. Dialkyl ether delivery agents
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
EP2094646A1 (en) * 2006-12-20 2009-09-02 AstraZeneca AB Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
KR101273200B1 (ko) 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US8263623B2 (en) * 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010067102A1 (en) * 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
GB0913345D0 (en) * 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
BR112012025703A2 (pt) * 2010-04-08 2016-07-05 Medicinova Inc métodos e composições para o tratamento de síndrome de intestino irritável
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
CN108892661B (zh) 2014-02-07 2023-03-14 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
CN111902404A (zh) 2018-02-07 2020-11-06 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
JP2022538907A (ja) * 2019-07-01 2022-09-06 キュラセン セラピューティクス インコーポレイテッド βアドレナリンアゴニストおよびその使用方法
CN111548311B (zh) * 2020-06-04 2021-04-23 山西医科大学 一种小分子glp-1r激动剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686353B1 (en) * 1996-05-20 2004-02-03 Teijin Intellectual Property Center Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
US6804980B2 (en) * 2002-10-16 2004-10-19 Marshall R. Bulle Metal stock bender twister adaptor
EP1615881A2 (en) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0324886D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
WO2005092861A1 (en) * 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1595873A1 (de) * 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
JP2008510015A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物

Also Published As

Publication number Publication date
TW200745084A (en) 2007-12-16
EP2013197A1 (en) 2009-01-14
WO2007102771A1 (en) 2007-09-13
UY30195A1 (es) 2007-10-31
JP2009529042A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
AR059956A1 (es) Derivados de fenetalonamina , procesos de preparacion y composiciones farmaceuticas que los contienen
AR044496A1 (es) N-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
AR073314A1 (es) Derivados de indazol o de 4,5,6,7-tetrahidro-indazol
AR070079A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas con mtor quinasa y/o p13k
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
ECSP19020228A (es) Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1
AR064636A1 (es) Nuevos compuestos 621
AR067444A1 (es) Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas
CY1120478T1 (el) Παραγωγα 2,6-υποκατεστημενης πουρινης και η χρηση αυτων στην αγωγη υπερπλαστικων διαταραχων
AR063332A1 (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11b-hsd1, un proceso de preparacion y una composicion farmaceutica en base al compuesto
AR067443A1 (es) Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR057977A1 (es) Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina. composiciones farmaceuticas.
AR061900A1 (es) Compuestos de azabencimidazolilo y composicion farmaceutica
AR070014A1 (es) Derivados de piridina, su preparacion y uso
CY1118390T1 (el) Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου
AR051393A1 (es) Adeninas sustituidas y sus usos
MX2018005239A (es) Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f][1,2,4]triazinona como inhibidores de fosfodiesterasa y sus usos.
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR054797A1 (es) Derivados de quinolina, composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de infecciones virales por virus de la familia flaviviridae, tal como hcv.
AR050603A1 (es) Aminas policiclicas sustituidas con arilo, procedimientos para su preparacion y su uso como medicamentos
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
CO5290258A1 (es) Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados
AR059521A1 (es) Ariltienopirimidinas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR034547A1 (es) Derivados de indolin-2-ona, su utilizacion, procedimiento para su preparacion, composicion farmaceutica que lo contiene, medicamento que consiste en dicho derivado, y un producto que contiene dicho derivado y un antagonista de los receptores de la vasopresina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal